Mission Bio partnered with Abiosciences to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers in China. The goal is to combine Mission Bio’s single-cell DNA and multi-omics capabilities with Abiosciences’ artificial intelligence technology to uncover new disease signatures and address therapeutic resistance. These new capabilities can be leveraged in patient stratification for clinical trials and, potentially, as a companion diagnostic tool, according to officials at both companies.

Mission Bio’s Tapestri® platform is a commercialized multi-omics product for  analyzing DNA and protein simultaneously from the same sample at single-cell resolution. Academic teams have described a range of clinical research use cases for Tapestri-based single-cell multi-omics assays, such as matching patients with leukemia to personalized care that reduced mortality in a clinical trial, and screening for dangerous cancer clones linked to therapeutic resistance, said Yan Zhang, PhD, CEO of Mission Bio.

Abiosciences will leverage its AI platform and bioinformatics methodology to create an analytical algorithm to try to gain deeper and more comprehensive insights into disease progression, development of resistance, and minimal residual disease after single-cell multi-omics analysis for researchers in China. Mission Bio will support Abiosciences with the Tapestri platform, custom panels, and R&D expertise.

Previous articlePulmonary Edema Could Be Countered by Cystic Fibrosis Drug
Next articleVascularized Islet Cell Implant Device for T1D Therapy Avoids Systemic Immunosuppression